IN VITRO DIAGNOSTIC QA PLAN SHOULD INCLUDE TREND ANALYSIS
This article was originally published in The Gray Sheet
Executive Summary
IN VITRO DIAGNOSTIC QA PLAN SHOULD INCLUDE TREND ANALYSIS to determine whether there are system failures that can be corrected, FDA's Center for Devices and Radiological Health says in a final draft of the IVD good manufacturing practices guide. Suggesting trend analysis as a way to comply with the requirements of the GMP regulation, FDA says that "product and process accept/reject data results, along with information from complaint files collected through various documented process and control systems, are evaluated by appropriate methods (e.g., trend analysis) to determine if there are recurring problems or process drift which warrant corrective action."
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.